MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · IEX Real-Time Price · USD
42.49
+0.24 (0.57%)
Apr 26, 2024, 4:00 PM EDT - Market closed
MLTX Employees
MoonLake Immunotherapeutics had 50 employees on December 31, 2023. The number of employees increased by 30 or 150.00% compared to the previous year.
Employees
50
Change (1Y)
30
Growth (1Y)
150.00%
Revenue / Employee
n/a
Profits / Employee
-$881,582
Market Cap
2.78B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| QuidelOrtho | 7,100 |
| Premier | 2,800 |
| Neogen | 2,640 |
| Certara | 1,391 |
| Indivior | 1,164 |
| PROCEPT BioRobotics | 626 |
| MorphoSys AG | 524 |
| Summit Therapeutics | 105 |
MLTX News
- 17 days ago - MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions - GlobeNewsWire
- 17 days ago - MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions - Business Wire
- 6 weeks ago - MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day - GlobeNewsWire
- 7 weeks ago - MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 - GlobeNewsWire
- 2 months ago - MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 - GlobeNewsWire
- 2 months ago - MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) - GlobeNewsWire
- 5 months ago - MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update - GlobeNewsWire
- 6 months ago - MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis - GlobeNewsWire